191 related articles for article (PubMed ID: 26464872)
1. Reduced Risk of Parkinson's Disease in Users of Calcium Channel Blockers: A Meta-Analysis.
Gudala K; Kanukula R; Bansal D
Int J Chronic Dis; 2015; 2015():697404. PubMed ID: 26464872
[TBL] [Abstract][Full Text] [Related]
2. Risk of Parkinson's Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies.
Mullapudi A; Gudala K; Boya CS; Bansal D
J Neurodegener Dis; 2016; 2016():5780809. PubMed ID: 27516917
[TBL] [Abstract][Full Text] [Related]
3. Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis.
Lang Y; Gong D; Fan Y
Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):559-66. PubMed ID: 25845582
[TBL] [Abstract][Full Text] [Related]
4. Calcium channel blockers and Parkinson's disease: a systematic review and meta-analysis.
Lin J; Pang D; Li C; Ou R; Yu Y; Cui Y; Huang J; Shang H
Ther Adv Neurol Disord; 2024; 17():17562864241252713. PubMed ID: 38770432
[TBL] [Abstract][Full Text] [Related]
5. Systematic review with meta-analysis: the association between the use of calcium channel blockers and gastrointestinal bleeding.
He Y; Chan EW; Leung WK; Anand S; Wong IC
Aliment Pharmacol Ther; 2015 Jun; 41(12):1246-55. PubMed ID: 25898902
[TBL] [Abstract][Full Text] [Related]
6. Statin use and risk of Parkinson's disease: A meta-analysis.
Sheng Z; Jia X; Kang M
Behav Brain Res; 2016 Aug; 309():29-34. PubMed ID: 27131781
[TBL] [Abstract][Full Text] [Related]
7. Association Between the Overall Risk of Prostate Cancer and Use of Calcium Channel Blockers: A Systematic Review and Meta-analysis.
Yang H; Yu Y; Hu X; Wang W; Yang X; Liu H; Ren L; Zhang X; Feng X; Liu L
Clin Ther; 2020 Sep; 42(9):1715-1727.e2. PubMed ID: 32807506
[TBL] [Abstract][Full Text] [Related]
8. Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: A meta-analysis of prospective studies.
Hussain S; Singh A; Rahman SO; Habib A; Najmi AK
Neurosci Lett; 2018 Apr; 671():120-127. PubMed ID: 29452176
[TBL] [Abstract][Full Text] [Related]
9. Use of calcium channel blockers and Parkinson's disease.
Pasternak B; Svanström H; Nielsen NM; Fugger L; Melbye M; Hviid A
Am J Epidemiol; 2012 Apr; 175(7):627-35. PubMed ID: 22387374
[TBL] [Abstract][Full Text] [Related]
10. Beta-blockers for hypertension.
Wiysonge CS; Bradley H; Mayosi BM; Maroney R; Mbewu A; Opie LH; Volmink J
Cochrane Database Syst Rev; 2007 Jan; (1):CD002003. PubMed ID: 17253471
[TBL] [Abstract][Full Text] [Related]
11. The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies.
Rotshild V; Azoulay L; Zarifeh M; Masarwa R; Hirsh-Raccah B; Perlman A; Muszkat M; Matok I
Drug Saf; 2018 Jun; 41(6):555-564. PubMed ID: 29484611
[TBL] [Abstract][Full Text] [Related]
12. The Risk for Prostate Cancer With Calcium Channel Blockers: A Systematic Review, Meta-Analysis, and Meta-Regression.
Rotshild V; Rabkin N; Matok I
Ann Pharmacother; 2023 Jan; 57(1):16-28. PubMed ID: 35645169
[TBL] [Abstract][Full Text] [Related]
13. Statin use and risk of Parkinson's disease: a meta-analysis of observational studies.
Undela K; Gudala K; Malla S; Bansal D
J Neurol; 2013 Jan; 260(1):158-65. PubMed ID: 22820685
[TBL] [Abstract][Full Text] [Related]
14. Association between depression and the subsequent risk of Parkinson's disease: A meta-analysis.
Wang S; Mao S; Xiang D; Fang C
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():186-192. PubMed ID: 29859854
[TBL] [Abstract][Full Text] [Related]
15. Association between calcium channel blockers and breast cancer: a meta-analysis of observational studies.
Chen Q; Zhang Q; Zhong F; Guo S; Jin Z; Shi W; Chen C; He J
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):711-8. PubMed ID: 24829113
[TBL] [Abstract][Full Text] [Related]
16. Effect of calcium-channel blockers on the risk of active tuberculosis and mortality: systematic review and meta-analysis.
Meregildo-Rodriguez ED; Asmat-Rubio MG; Bardales-Zuta VH; Vásquez-Tirado GA
Front Pharmacol; 2024; 15():1298919. PubMed ID: 38303987
[No Abstract] [Full Text] [Related]
17. Calcium channel blocker use and risk of Parkinson's disease.
Simon KC; Gao X; Chen H; Schwarzschild MA; Ascherio A
Mov Disord; 2010 Sep; 25(12):1818-22. PubMed ID: 20669249
[TBL] [Abstract][Full Text] [Related]
18. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers.
Makarounas-Kirchmann K; Glover-Koudounas S; Ferrari P
Clin Ther; 2009 Aug; 31(8):1652-63. PubMed ID: 19808126
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: a systematic review and meta-analysis.
Kow CS; Ramachandram DS; Hasan SS
Hypertens Res; 2022 Feb; 45(2):360-363. PubMed ID: 34754084
[TBL] [Abstract][Full Text] [Related]
20. Beta-blockers for hypertension.
Wiysonge CS; Bradley HA; Volmink J; Mayosi BM; Opie LH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002003. PubMed ID: 28107561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
